FDA Declines to Approve 2 More China-Tested Drugs

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. Food & Drug Administration (FDA) on Monday declined to approve two cancer treatment drugs developed by drugmakers who tested their products mainly in China.

The federal agency’s rejection is a sign of an increasingly tough U.S stance on drugs being tested solely in China, after some drugmakers moved to save costs by conducting clinical trials only in China.